Three EGFR tyrosine kinase inhibitors have been compared to standard chemotherapy as
up-front treatment in patients with advanced EGFR-positive NSCLC. We performed a …

Abstract Background Tyrosine-kinase inhibitors (TKIs) have become the cornerstone
treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations …

Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …

Objectives Epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung
cancer (NSCLC) is a specific lung cancer subtype characterized by sensitivity to treatment …

The first-in-human dosing of the Epidermal Growth Factor Receptor tyrosine kinase inhibitor
(EGFR-TKI) ZD1839 (later gefitinib) goes back to April 1998, by now almost 20 years ago. In …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …

First-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is a standard
treatment for patients with activating EGFR mutations. Six randomized studies have …

Objective The aim of this meta-analysis was to evaluate efficacy and toxicity of epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with …

7072 Background: EGFR mutations are associated with better response and in some studies
(mainly Asian) also with prolonged survival after gefitinib therapy in patients with advanced …

Background The objective of this study was to investigate real-world EGFR mutation testing
in patients with metastatic non-small cell lung cancer (NSCLC) upon progression on …